Hong Kong-listed AI medical stock buys back the first share! YIDU TECH (02158) repurchased nearly 15 million Hong Kong dollars on March 19, deepening regional layout with Guangxi Medical University.

On March 19, YIDU TECH (02158) once again increased its share buyback, spending nearly 15 million Hong Kong dollars on the same day, maintaining a high-frequency, high-value buyback pace, demonstrating a strong recognition of the company's long-term value. As the first company in the Hong Kong stock market to buy back AI medical stocks, YIDU TECH has been leading the market in buyback performance since 2026: completing 33 buybacks so far this year, with a total buyback amount of nearly 240 million Hong Kong dollars, ranking third in the Hong Kong stock market, behind only Xiaomi Group and Netease Music. The company's buyback intensity and sustainability lead other companies in the same industry, making it a benchmark for the return of value in the Hong Kong stock market in the technology and medical sectors. On the business front, progress is accelerating. Recently, the company reached a deep cooperation agreement with Guangxi Medical University to establish the Guangxi Medical Artificial Intelligence Research Institute, focusing on clinical diagnosis and treatment, talent training, and upgrading regional medical services, promoting the scale deployment of AI medical technology in Guangxi and the ASEAN region. At the same time, the steady advancement of Medical Wisdom Loop clinical evidence-based intelligent body in clinical validation and scenario coverage continues to strengthen technological barriers and commercial foundations. On the capital side, firm buybacks stabilize expectations, while on the business side, cooperation and growth are increasing. YIDU TECH is driving growth through the three pillars of "high rate buyback + high-impact product launches + regional strategic partnerships," fully unlocking the growth potential of the AI healthcare leader, and creating long-term value for shareholders and the market.